What is Castle Biosciences's gross profit margin?

What is Castle Biosciences's latest dividend and current dividend yield?

What were the key takeaways from Castle Biosciences’s earnings call?

What factors drove the changes in Castle Biosciences's revenue and profit?

What were the key takeaways from Castle Biosciences's earnings call?

What does Castle Biosciences do and what are its main business segments?

What is the revenue and EPS growth rate for Castle Biosciences year over year?

What is the market's earnings forecast for Castle Biosciences next quarter?

- **$33B Market Launch**: AdvanceAD-Tx targets 13.2M U.S. atopic dermatitis patients.
- **Revenue Growth**: Q3 up 36% YoY, melanoma test hits record 10,459 reports.
- **Updated Guidance**: 2025 revenue raised to $327M-$335M.
- **Cash Flow Strength**: Positive net cash flow from operations.
- **Strategic Focus**: Melanoma growth, TissueCypher expansion, FDA melanoma approval pursuit.

**【CEO Summary Section】**
- Launched **AdvanceAD-Tx**, a first-in-class test for systemic treatment selection in moderate to severe atopic dermatitis, targeting a $33B U.S. market with 13.2M patients.
- Q3 revenue reached **$83M**, with test report volumes up 36% YoY.
- **DecisionDx-Melanoma** achieved record 10,459 reports (12% YoY growth), while **TissueCypher** grew 75% YoY to 10,609 reports.
- **SCC test volumes** remained flat due to melanoma focus, but commercial claims began.

**【CFO Financial Commentary】**
- Updated 2025 revenue guidance to **$327M-$335M** (up from $310M-$320M).
- Gross margin: 74.7% (GAAP), 76.8% (adjusted).
- Operating expenses rose 11% YoY to **$89.8M**, driven by sales and R&D growth.
- Net loss: **$0.5M**, with positive cash flow from operations.

**【Q&A Highlights】**
- **AdvanceAD-Tx** expects 10-15% Medicare patients, with phased launch in 2026.
- **SCC test** volumes stable due to clinical value, with modest commercial claims.
- **Melanoma test growth** driven by refocused sales team, targeting high single-digit YoY growth.
- **TissueCypher** penetration growing, with 75% YoY growth.
- **FDA approval** for melanoma test to support biomarker laws, no immediate SCC test stoppage.

Castle Biosciences, Inc. (CSTL) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

CSTL

CSTL fundamentals

You can ask Aime